Vistagen Therapeutics, Inc.
VTGN· Nasdaq
VTGNVistagen Therapeutics, Inc.
Filed Feb 17, 2015 · 10-Q · 48 days after period end · 0001415889-15-000568
| Metric | Q3 2015 | Q3 2014 | Q3 2010 |
|---|---|---|---|
| Revenue | — | — | $584.77K |
| Net Income | -$1.09M | $131.00K | -$3.39M |
| EPS Diluted | -$1.08 | -$0.02 | -$0.65 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Dec 31, 2014 · filed Feb 17, 2015 · 48 d after period end
